Intestine Organ Type to Boost Organoids Market Growth
The intestines are vital organs derived from definitive endoderm and are subdivided into small and large intestines. Intestinal organoids are self-organized 3-dimensional structures that partially recapitulate the original tissue’s identity, cell heterogeneity, and cell behavior. The small intestine is a major organ that regulates digestive function and nutrient absorption. Intestinal organoid technology has dramatically enhanced research into tissue homeostasis, cell-to-cell interactions, differentiation, and physiology due to the higher prevalence of Inflammatory Bowel Diseases (IBDs), including ulcerative colitis and Crohn’s disease, which are rapidly surging across both developed and developing countries. Intestinal organoids have been used for organ development, disease research, transplantation, and regenerative medicines.
Furthermore, intestinal organoids represent a capable in vitro model for experimental research and development on functional gastrointestinal processes, such as drug absorption, enteroendocrine secretion, assessment of nutrient transport, and intracellular signaling. According to data by the European Federation of Crohn’s & Ulcerative Colitis Association (EFCCA), published in May 2022, ~10 million people worldwide live with IBDs. The data also stated that Crohn’s disease or ulcerative colitis was common in the UK in 2022, with a rate of 1 in every 123 people. According to the same source, the incidence is nearly the same in the US and other Western countries. Thus, the advances in intestinal organoid research, such as 3D microtissue models and others, are leading to significant trends in the organoids market.
Organoids Market: Segmental Overview
The “global organoids market” is segmented based on organ type, application, source, type, and geography.
By organ type, the organoids market is divided into intestine, stomach, liver, pancreas, lung, brain, kidney, and others. In 2022, the intestine segment held the largest share of the market and is anticipated to register the highest CAGR during 2022–2030 due to a dramatic shift in the availability of model systems and tools in the last few years that are used for study and research purpose of the intestinal epithelium. The research, development, and adoption of intestinal organoid cultures have led to the market growth. IBDs, such as Crohn’s disease (CD) and ulcerative colitis (UC), are common worldwide. In the last decade, there has been a dramatic shift in the availability of tools and model systems that are used to study the intestinal epithelium. The development and adoption of intestinal organoid cultures have been the core of this movement. Simultaneously, various experimental techniques—including novel genetic manipulation tools, in vitro disease modeling approaches, innovative co-culture systems with autologous cell types or bacteria, and viral infection models—were developed to evaluate a scientifically synergistic effect with intestinal organoid cultures. The aforementioned factors are responsible for driving the organoids market for the segment.
Based on application, the organoids market is divided into pathology, infectious disease, regenerative medicine, developmental biology disease, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. In 2022, the developmental biology disease segment held the largest market share by application. The progress of the organoids market for developmental biology applications is attributed to the technological advancements in the 3-dimensional bioprinting method, which has shown a lucrative potential to facilitate organ development, as the timeframe required for organoid culturing is less than traditional tissue culture methods.
Based on source, the organoids market is divided into pluripotent stem cells and organ-specific adult stem cells. In 2022, the pluripotent stem cells segment held a larger market share. Pluripotent stem cells have numerous biomedical applications in drug research, drug screening, disease modeling, toxicological studies, and cell target therapy. These cells are potentially used in cell and gene replacement therapy for treating patients with cellular diseases. Thus, they are widely used for developing an organoid process in vitro. Furthermore, pluripotent cells are used in biobanking for preserving patient-derived stem cells in various applications, which can be used in therapeutics and research processes.
Based on type, the organoids market is divided into instruments, consumables, and services. In 2022, the consumables segment held the largest share of the market. Consumables include cell media, plates, centrifuge tubes, buffers, reagents, serum, serological pipets, storage vessels, centrifuge tubes, filter systems, chemically defined media, classical media, and xeno-free/animal components. Major players focus on strategic growth, such as increasing R&D activities, launching new products, and collaborating with other players to enhance their product offerings and expand their geographical footprint. For instance, Thermo Fisher Scientific, Inc. and Sartorius AG offer media-related products for stem cell research and stem cell-based therapies.
Organoids Market: Competitive Landscape and Key Developments
STEMCELL Technologies Inc. Hubrecht Organoid Technology, Definigen, Cellesce Ltd, Organoid Therapeutics, 3Dnamics Inc., Corning Inc., Merck KGaA, Thermo Fisher Scientific Inc., and InSphero are among the leading companies operating in the organoids market. These players focus on various expanding and diversifying strategies to increase their market presence and acquire a novel customer base, tapping prevailing business opportunities in the organoids market.
Market players are launching new products to the market. Below are a few instances:
- In May 2023, F. Hoffmann-La Roche AG, a Switzerland-based company, opened a new institute to advance research in human model systems that are tiny 3D or 2D living replicas of human tissues and organs generated from human stem cells. This new research institute will accelerate research and development activities in the area of human model systems such as organoids.
- In April 2023, Molecular Devices, LLC. and HUB Organoids (HUB) announced a strategic collaboration enabling the development of next-generation three-dimensional biology technologies that help reduce pre-clinical to clinical drug attrition. Under the terms of this agreement, the molecular devices will license the cutting-edge ‘HUB Organoid Technology’ to work with patient-based intestinal organoids, expanding these devices beyond organoid types such as the heart and brain.